DuraStat builds a surgeon-invented instrument that automates suture passage to repair tears in the dura - the membrane around the brain and spinal cord - and help stop cerebrospinal fluid leaks before they start.
DuraStat, 1101 E. 6th St, Austin - a 14-person medical device company whose flagship instrument now sits on surgical shelves in all fifty states. Photographed here: the company wordmark.
Every spine surgeon knows the moment. During a procedure the dura mater - the thin, paper-like membrane that seals cerebrospinal fluid around the brain and spine - gets nicked. It is called an incidental durotomy, and if it isn't closed cleanly the fluid can leak for weeks, driving pain, readmissions, and cost. Repairing it means passing a curved needle through a membrane millimeters thick, often through an opening barely wide enough for a hand.
DuraStat exists to make that repair fast and reproducible. The company's namesake device consolidates the fiddly, multi-step suturing sequence into a single button press: the surgeon positions the instrument, activates it, and the needle passes on a pre-selected path - no wrist rotation required. The result is a precise, atraumatic, sutured closure designed to prevent persistent CSF leaks, even when access is limited.
It was not dreamed up in a lab. DuraStat was invented by practicing spine surgeons Greg Anderson, MD and Mark Kurd, MD, and engineered for scale with input from Kevin Foley, MD and Alex Lukianov. That surgeon-first origin runs through everything the 14-person Austin company builds.
The surgeon places the device at the dural tear with the needle pre-set on its path - no supination, no awkward wrist angle.
A single button press drives the automated suture passage through the membrane in a controlled, predictable arc.
The surgeon repeats along the tear, placing sutures with consistent spacing and minimized tissue disruption.
Sutures are tied off to form a reproducible primary closure engineered to hold fluid and prevent CSF leaks.
The dural repair device. Automates suture passage to close incidental durotomies and planned dural openings - intradural tumor resection, tethered cord, transsphenoidal approaches - preventing persistent CSF leaks.
A minimally invasive spine fascial closure device that applies the same precision-suturing approach to closing the fascia through small incisions.
A next-generation version of the flagship device planned for launch alongside the Medtronic commercial partnership and the full-scale release of TissueStat.
Much of the dural repair market is built around sealants and grafts - products that patch or reinforce a tear. DuraStat takes a different tack: it helps surgeons perform an active, sutured primary closure quickly enough that it stays practical even in tight surgical corridors. Here is how the approach compares.
| Attribute | DuraStat | Conventional hand suturing | Sealants / grafts |
|---|---|---|---|
| Closure type | Active sutured primary | Sutured primary | Patch / reinforce |
| Wrist rotation | Eliminated | Required | N/A |
| Works in limited access | Designed for it | Difficult | Variable |
| Steps | Consolidated to a button press | Multiple manual steps | Application-based |
| Reproducibility | Pre-selected needle path | Surgeon-dependent | Depends on adhesion |
Comparison reflects DuraStat's publicly described design goals; individual clinical outcomes vary by case and surgeon.
DuraStat is a B2B medical device manufacturer. It designs, patents, and makes surgical instruments sold to hospitals and surgical facilities - increasingly through the group purchasing contracts that gatekeep hospital shelves.
Those credentials stacked up fast: a Vizient Innovative Technology contract in 2022 and a Premier, Inc. Breakthrough Technology agreement in 2023. Then, in November 2024, the company signed an exclusive U.S. commercial partnership with Medtronic's Cranial & Spinal Technologies business - handing a 14-person company one of medtech's largest distribution engines.
Customers are spine surgeons and neurosurgeons, and the facilities where they operate - now spanning all 50 states.
The company is established in Austin to commercialize a surgeon-invented dural repair device.
Orthopedics This Week names DuraStat Best Technology in Spine.
DuraStat closes an over $5M Series B in April and lands a Vizient Innovative Technology contract in July.
DuraStat is awarded a Breakthrough Technology agreement with Premier, Inc.
DuraStat enters an exclusive U.S. commercial partnership with Medtronic's Cranial & Spinal Technologies business, effective November.
A handheld surgical device that automates suture passage to repair tears in the dura mater during spine and neurosurgical procedures, helping prevent cerebrospinal fluid (CSF) leaks.
It was invented by spine surgeons Greg Anderson, MD and Mark Kurd, MD, and developed for scale with input from Kevin Foley, MD and Alex Lukianov. Adam Azzara is the CEO.
Austin, Texas, at 1101 E. 6th St. The company has about 14 employees.
DuraStat has raised roughly $9.5M, including an over $5M Series B round closed in April 2022.
In November 2024 DuraStat entered an exclusive U.S. commercial partnership with Medtronic's Cranial & Spinal Technologies business to distribute DuraStat and TissueStat and support a second-generation launch.
Sources: durastat.com, PR Newswire, MassDevice, FinSMEs, Ortho Spine News, BioSpace, Orthopedics This Week.